Immunome Inc.
Immunome (IMNM) amended its license with Bristol-Myers Squibb, acquiring full patent rights to AL101 and varegacestat for $20M and 4.43M shares. The deal eliminates future milestone and royalty obligations, simplifying the company's economics. Immunome also agreed to register the issued shares for resale by November 16, 2026.
Immunome Inc. (IMNM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment to License Agreement On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agree
Stifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and $24 price target, citing uncertainty around its lead drug and pipeline. The stock trades at $21.51, down 10% in a week but up 87% over a year. The FDA accepted Immunome's New Drug Application for varegacestat, with a target action date of April 28, 2027. The company also began a Phase 1 trial for IM-3050. H.C. Wainwright maintains a Buy rating and $40 target.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IMNM (Immunome Inc.). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent IMNM coverage spans insider activity, corporate actions and regulation.
In the last 30 days, IMNM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($334K). The most active reporter was Higgins Jack, Chief Scientific Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The cash outflow and share dilution likely pressure IMNM stock lower in the short term.
Dilution from share issuance may pressure the stock, but the $20M cash infusion could provide near‑term runway.
Positive regulatory and clinical data likely lift the stock.
Routine 10b5-1 insider selling by a director, likely more about liquidity than fundamentals, but it can still weigh on near-term sentiment.
Regulatory milestone plus Phase 3 efficacy detail increases probability of near-term approval pathway for varegacestat, likely supporting risk-on positioning.
AlphAI scores every news story that mentions IMNM with an AI model for sentiment and relevance, and aggregates insider trades from Immunome Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunome (IMNM) amended its license with Bristol-Myers Squibb, acquiring full patent rights to AL101 and varegacestat for $20M and 4.43M shares. The deal eliminates future milestone and royalty obligations, simplifying the company's economics. Immunome also agreed to register the issued shares for resale by November 16, 2026.
2 min readImmunome Inc. (IMNM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment to License Agreement On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agree
2 min readStifel initiated coverage on Immunome Inc. (IMNM) with a Hold rating and $24 price target, citing uncertainty around its lead drug and pipeline. The stock trades at $21.51, down 10% in a week but up 87% over a year. The FDA accepted Immunome's New Drug Application for varegacestat, with a target action date of April 28, 2027. The company also began a Phase 1 trial for IM-3050. H.C. Wainwright maintains a Buy rating and $40 target.
2 min readBarchas Isaac sold 72,416 indirectly-held shares of Immunome Inc. (IMNM) at an average of $26.21 ($26.07–$26.23, $1.90M total) across 2 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readImmunome Inc. (IMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update August 11, 2026 • Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors • Detailed P
4 min readBarchas Isaac sold 36,088 indirectly-held shares of Immunome Inc. (IMNM) at $26.06 ($0.94M total) across 2 trades over 2026-08-06 to 2026-08-07 under a Rule 10b5-1 trading plan.
2 min readHorn Kinney (CHIEF BUSINESS OFFICER) sold 90,616 shares of Immunome Inc. (IMNM) at $25.09 ($2.27M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readImmunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.
7 min readBarchas Isaac sold 100,000 indirectly-held shares of Immunome Inc. (IMNM) at an average of $24.13 ($24.11–$24.20, $2.41M total) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readLechleider Robert (Chief Medical Officer) sold 55,000 shares of Immunome Inc. (IMNM) at an average of $22.62 ($21.95–$23.44, $1.24M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
2 min read
